[¹⁸F]FDG-PET/CT in patients affected by retroperitoneal fibrosis: a bicentric experience.
Details
Serval ID
serval:BIB_6E83097680EF
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
[¹⁸F]FDG-PET/CT in patients affected by retroperitoneal fibrosis: a bicentric experience.
Journal
Japanese journal of radiology
ISSN
1867-108X (Electronic)
ISSN-L
1867-1071
Publication state
Published
Issued date
06/2012
Peer-reviewed
Oui
Volume
30
Number
5
Pages
415-421
Language
english
Notes
Publication types: Journal Article ; Multicenter Study
Publication Status: ppublish
Publication Status: ppublish
Abstract
The aim of our study was to assess the feasibility and usefulness of 2-[(18)F]-fluoro-2-deoxy-D: -glucose positron emission tomography computed tomography ([(18)F]FDG-PET/CT) in patients affected by retroperitoneal fibrosis.
We retrospectively evaluated 25 patients studied in two centers: 18 underwent [(18)F]FDG-PET/CT as initial evaluation, three during follow-up, three during steroid therapy, and one to re-evaluate the disease. Among the group who underwent initial evaluation, ten underwent a second [(18)F]FDG-PET/CT after steroid therapy.
[(18)F]FDG-PET/CT was positive in 18 patients and negative in seven. Among the ten patients who underwent a second study after steroid therapy, six showed complete metabolic response, three partial response, and one no significant maximum standardized uptake value (SUV(max)) reduction.
Our preliminary results show that [(18)F]FDG-PET/CT is feasible and suitable for evaluating retroperitoneal fibrosis and is useful in assessing therapy response. Larger studies are desirable to confirm these findings and to determine the appropriate position of [(18)F]FDG-PET/CT in the diagnostic flow chart for this disease.
We retrospectively evaluated 25 patients studied in two centers: 18 underwent [(18)F]FDG-PET/CT as initial evaluation, three during follow-up, three during steroid therapy, and one to re-evaluate the disease. Among the group who underwent initial evaluation, ten underwent a second [(18)F]FDG-PET/CT after steroid therapy.
[(18)F]FDG-PET/CT was positive in 18 patients and negative in seven. Among the ten patients who underwent a second study after steroid therapy, six showed complete metabolic response, three partial response, and one no significant maximum standardized uptake value (SUV(max)) reduction.
Our preliminary results show that [(18)F]FDG-PET/CT is feasible and suitable for evaluating retroperitoneal fibrosis and is useful in assessing therapy response. Larger studies are desirable to confirm these findings and to determine the appropriate position of [(18)F]FDG-PET/CT in the diagnostic flow chart for this disease.
Keywords
Adult, Aged, Aged, 80 and over, Female, Fluorodeoxyglucose F18, Humans, Male, Middle Aged, Multimodal Imaging, Positron-Emission Tomography, Radiopharmaceuticals, Retroperitoneal Fibrosis/diagnostic imaging, Retroperitoneal Fibrosis/therapy, Tomography, X-Ray Computed
Pubmed
Web of science
Create date
20/08/2017 22:04
Last modification date
20/08/2019 15:27
Usage data
